Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Joana, Gostkorzewicz"'
Publikováno v:
International Journal of Technology Assessment in Health Care. 39
Objectives Value-based agreements (VBAs) link access, reimbursement, or price to the real-world usage and impact of a medicine, thereby enabling patient access while reducing clinical or financial uncertainty for the payer. VBAs have the potential to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa326a02c11244ba19cf59787273af31
https://doi.org/10.1017/s0266462323000260
https://doi.org/10.1017/s0266462323000260
Autor:
María Teresa Gómez-Casares, Juan Carlos Hernández-Boluda, Antonio Jiménez-Velasco, Joaquin Martínez-López, María Giovanna Ferrario, Irmina Gozalbo, Joana Gostkorzewicz, Rudi Subirá
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 5, Iss 2 (2017)
**Introduction:** Primary myelofibrosis (MF) is a rare hematologic disease belonging to the group of Philadelphia-negative chronic myeloproliferative neoplasms. Identification of the Janus Kinase (JAK) gene mutations inaugurated a new era in the targ
Externí odkaz:
https://doaj.org/article/1081428271f1429e834f40fea1d7798b
Autor:
Cristina Díaz de Heredia, Josep Maria Ribera Santasusana, Alejandra de Andrés Saldaña, Diana Martínez Llinàs, Nuria García-Muñoz, Joana Gostkorzewicz
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Josep Maria Ribera Santasusana,1 Alejandra de Andrés Saldaña,2 Nuria García-Muñoz,3 Joana Gostkorzewicz,2 Diana Martínez Llinàs,3 Cristina Díaz de Heredia4 1Clinical Hematology Department, Catalan Institute of Oncology - Hospital Germans Trias
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1212209855158098936d0e949a7d38ec
http://europepmc.org/articles/PMC7237114
http://europepmc.org/articles/PMC7237114
Autor:
Jordi Esteve, Roberta Di Nicolantonio, Ainhoa Arenaza, Joaquin Martinez-Lopez, Aída Moure-Fernández, Jorge Sierra, Joana Gostkorzewicz, Joan Lluís Vinent, Raúl Diez, Pau Montesinos, Diana Martínez Llinàs, Carlos Martínez
Publikováno v:
ClinicoEconomics and Outcomes Research. 11:683-694
Purpose: The addition of midostaurin to standard chemotherapy (cytarabine and daunorubicin) has shown significant improvements in the survival of patients with acute myeloid leukemia with the FLT3 mutation (FLT3-AML). The objective of this study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::885e72b22a53762480cec83fd271530f
https://doi.org/10.2147/ceor.s222879
https://doi.org/10.2147/ceor.s222879
Autor:
Ainhoa, Arenaza, Raúl, Diez, Jordi, Esteve, Roberta, Di Nicolantonio, Joana, Gostkorzewicz, Carlos, Martínez, Diana, Martínez Llinàs, Joaquin, Martinez-Lopez, Pau, Montesinos, Aída, Moure-Fernández, Jorge, Sierra, Joan Lluís, Vinent
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Purpose The addition of midostaurin to standard chemotherapy (cytarabine and daunorubicin) has shown significant improvements in the survival of patients with acute myeloid leukemia with the FLT3 mutation (FLT3-AML). The objective of this study was t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eb972179d6385c4bbfc366750d082620
https://pubmed.ncbi.nlm.nih.gov/32009807
https://pubmed.ncbi.nlm.nih.gov/32009807
Autor:
Irene Martínez, Elena Galve-Calvo, Eva González-Haba, Joana Gostkorzewicz, Alejandro Pérez-Mitru
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Elena Galve-Calvo,1 Eva González-Haba,2 Joana Gostkorzewicz,3 Irene Martínez,4 Alejandro Pérez-Mitru4 1Medical Oncology Service, Basurto University Hospital, Bilbao, Spain; 2Pharmacy Department, Hospital Universitario Gregorio Marañón, Madrid, S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::401922e7d2d9ee02ac4c76f8d12be54b
https://www.dovepress.com/cost-effectiveness-analysis-of-ribociclib-versus-palbociclib-in-the-fi-peer-reviewed-article-CEOR
https://www.dovepress.com/cost-effectiveness-analysis-of-ribociclib-versus-palbociclib-in-the-fi-peer-reviewed-article-CEOR
Autor:
B. Sánchez-González, M.T. Álvarez, Joana Gostkorzewicz, M. Morros, C. Pascual-Izquierdo, R. Di Nicolantonio, M. Artés
Publikováno v:
Value in Health. 22:S909
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae120c71bb784eb8201771939cd96760
https://doi.org/10.1016/j.jval.2019.09.2669
https://doi.org/10.1016/j.jval.2019.09.2669
Autor:
Erik Smets, Francisco Ledesma, Anita Brogan, Andrew Hill, Ines Adriaenssen, Anthony W. Sawyer, Joana Gostkorzewicz, Pere Domingo-Pedrol
Publikováno v:
Enfermedades Infecciosas y Microbiología Clínica. 31:430-436
Resumen Introduccion Las guias GESIDA proponen pautas preferentes de inicio de tratamiento antirretroviral en pacientes infectados por el VIH. El objetivo de este analisis es comparar los costes y la eficacia de darunavir/r QD frente a otros inhibido
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::538d11ff4bbb3cdf54196f729544916e
https://doi.org/10.1016/j.eimc.2012.11.001
https://doi.org/10.1016/j.eimc.2012.11.001
Autor:
Fernando Rivera, Javier Sastre, Pilar Bretes Garcia, Ferran Pérez-Alcántara, Joana Gostkorzewicz, Alfredo Carrato, Patricia Benedit, Rafael López, Teresa Macarulla
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 15(4)
The PANCOSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine (GEM) versus GEM alone in the treatment of patients with metastatic pancreatic cancer in Spain. Efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae940e1ef0919ea6eae574521e4d8411
https://pubmed.ncbi.nlm.nih.gov/25991037
https://pubmed.ncbi.nlm.nih.gov/25991037
Autor:
Juan Pasquau, Anne Anceau, Christiane Moecklinghoff, Joana Gostkorzewicz, Francisco Ledesma, Andrew F. Hill
Publikováno v:
Applied Health Economics and Health Policy. 10(2):139-141
In an article from a previous issue of this journal, the potential economic impact of using darunavir/ritonavir (DRV/r) as monotherapy for treatment of HIV-1 infection was estimated, using UK prices.[1] In this analysis, we have adapted the scenario
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e3ef8fef2d603aa4f1d0456632361f7
http://healtheconomics.adisonline.com/pt/re/ahe/fulltext.00148365-201210020-00006.htm
http://healtheconomics.adisonline.com/pt/re/ahe/fulltext.00148365-201210020-00006.htm